Treace Medical Concepts Logo
US89455T1097
A3CM04
TMCI

Treace Medical Concepts

Loading quotes...

Forecast

The analysts' average price target is €5.92 (-74.13%). The median is €5.92 (-74.13%).

Buy
  3
Hold
  5
Sell
  1

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • Treace Medical beats Q2 forecasts; shares jump about 24% premarket

    Treace Medical reported Q2 revenue of $45.4 million and an adjusted loss of $0.24 per share, with both revenue and EPS beating consensus estimates. The company cut operating expenses by 8% and reduced cash burn since the start of the year by 57%, lowering the net loss to $15.9 million. Treace slightly raised its full-year revenue guidance to $204–212 million and narrowed the adjusted EBITDA loss to $3–5 million, citing accelerated case volume and several product launches as drivers. The stock rose about 24% in premarket trading in response to the stronger results and the improved outlook. » More on de.investing.com


  • Treace Medical Concepts reports Q4 2025 revenue decline, stock rises slightly

    Treace Medical Concepts reported Q4 2025 revenue of $62.5 million, a 9% decline year‑over‑year, and a loss per share of $0.16, missing expectations. Gross margin remained stable at 80.6%, while operating expenses rose slightly to $56.3 million. The company attributed the revenue decline to a shift in the product mix toward lower‑priced offerings. The stock gained 0.48% in premarket trading, and Treace plans several product launches in 2026 (including Lapiplasty Lightning and IntelliGuide PSI) to support growth. » More on de.investing.com


  • Treace Medical adjusts strategy: product expansion and cost cuts to counter falling demand

    Treace Medical reports annual revenue of over $200 million but sees weaker demand for the Lapoplasty system. The company is expanding its portfolio for bunion treatments, introducing new lower-priced products, and stepping up surgeon training as well as AI-powered diagnostics with IntelliGuide. Financial measures include stable gross margins in the high-70% range and a 45% reduction in cash burn; further decisions are expected after the Q4 numbers. » More on de.investing.com


  • Treace Medical raises Q3 revenue 11% to $50.2m but remains loss-making

    Treace Medical reported Q3 2025 revenue up 11% to $50.2m, above analysts’ estimate of $49.66m. The company recorded a net loss of $16.3m, or $0.26 per share; gross margin fell to 79.1%. Adjusted EBITDA loss improved 49% to $2.6m. For 2025 Treace expects revenue of $211–213m and an adjusted EBITDA loss of $6.5–7.5m; management emphasizes a focus on profitability and market expansion. » More on de.investing.com


  • Treace Medical Concepts beats Q2 forecasts and shares rise after hours

    Treace Medical Concepts Inc. reported a Q2 2025 loss per share of $0.28 versus $0.29 expected and revenue of $47.4 million, topping estimates. Net loss and adjusted EBITDA improved significantly; the stock rose 3.84% after hours. For 2025, the company guides to $224–$230 million in revenue and breakeven on adjusted EBITDA, supported by new product launches and market expansion. » More on de.investing.com

Financials

In the last quarter, Treace Medical Concepts had revenue of €42.6M and net profit of -€11.09M
(EUR) September 2026
YoY
Revenue 42.6M 0.44%
Gross profit 33.86M 0.07%
Net profit -11.09M 20.07%
EBITDA -9.7M 6.52%

Fundamentals

Metric Value
Market capitalization
€264.93M
Number of shares
65.56M
52-week high/low
€4.95 - €1.06
Dividends No
Beta
1.56
P/E ratio
-5.16
PEG ratio
0.49
P/B ratio
4.72
P/S ratio
1.43

Company profile

Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of medical devices for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement. The company also provides Lapiplasty Mini-Incision precision system. In addition, it offers products to address ancillary surgical procedures, including akin osteotomies, weil osteotomies, intercuneiform stabilization, lesser tarsometatarsal joint fusions, and autograft bone harvesting, as well as for MTP fusion. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra Beach, Florida.

Name
Treace Medical Concepts
CEO
John T. Treace
Headquarters Ponte Vedra, fl
USA
Website
Sector
Consumer Discretionary
Industry
Household Durables
IPO
04/23/2021
Employees 450

Ticker symbols

Exchange Symbol
NASDAQ
TMCI
🍪

Parqet  uses cookies. Learn more